Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression

Biomedicine and Pharmacotherapy

Volumn 62, Issue 2, 2008, Pages 85-93

  Radhakrishnan, Vinodhkumar ^a,b   Song, Young Sun ^b   Thiruvengadam, Devaki ^a  

^a UNIVERSITY OF MADRAS   (India)

^b Inje University   (South Korea)

Author keywords

Cyclins; Histone hyperacetylation; Retinoblastoma protein (pRb)

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; PROTEIN P21; RETINOBLASTOMA PROTEIN; ROMIDEPSIN;

ACETYLATION; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; FLOW CYTOMETRY; HISTONE HYPERACETYLATION; HUMAN; HUMAN CELL; LUNG CARCINOMA; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN;

EID: 38949140475     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.06.002     Document Type: Article

References (50)

1. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., and Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2 (2003) 151-163
2. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 (2002) 287-299
3. Mariadason J.M., Corner G.A., and Augenlicht L.H. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60 (2000) 4561-4572
4. Marks P.A., Richon V.M., Miller T., and Kelly W.K. Histone deacetylase inhibitors. Adv Cancer Res 91 (2004) 137-168
5. Sasakawa Y., Naoe Y., Inoue T., Sasakawa T., Matsuo M., Manda T., et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 64 (2002) 1079-1090
6. Kosugi H., Ito M., Yamamoto Y., Towatari M., Ito M., Ueda R., et al. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice. Jpn J Cancer Res 92 (2001) 529-536
7. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Cancer Res 8 (2002) 718-728
8. Gallinari P., Di Marco S., Jones P., Pallaoro M., and Steinkühler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17 (2007) 195-211
9. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (2000) 1210-1216
10. Takahashi Y., Rayman J.B., and Dynlacht B.D. Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 14 (2000) 804-816
11. Grana X., and Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11 (1995) 211-219
12. Mittnacht S. Control of pRB phosphorylation. Curr Opin Genet Dev 8 (1998) 21-27
13. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13 (1997) 261-291
14. Lundberg A.S., and Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18 (1998) 753-761
15. Howard C.M., Claudio P.P., De Luca A., Stiegler P., Jori F.P., Safdar N.M., et al. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop 1. Cancer Res 60 (2000) 2737-2744
16. Yu C., Rahmani M., Conrad D., Subler M., Dent P., and Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102 (2003) 3765-3774
17. Byrd J.C., Shinn C., Ravi R., Willis C.R., Waselenko J.K., Flinn I.W., et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94 (1999) 1401
18. Aron J.L., Parthun M.R., Marcucci G., Kitada S., Mone A.P., Davis M.E., et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102 (2003) 652-658
19. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97 (2000) 10014-10019
20. Medina V., Edmonds B., Young G.P., James R., Appleton S., and Zalewski P.D. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57 (1997) 3697
21. Klisovic D.D., Katz S.E., Effron D., Klisovic M.I., Wickham J., Parthun M.R., et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 44 (2003) 2390-2398
22. Vinodhkumar R., Song Y.S., Ravikumar V., Ramakrishnan G., and Devaki T. Depsipeptide a histone deacetylase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chem Biol Interact 165 (2007) 220-229
23. Khan N., Hadi N., Afaq F., Syed D.N., Kweon M.H., and Mukhtar H. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 28 (2007) 163
24. Ping Yuan J., Hua Wang G., Hong Yang Y., Jun Tang R., Liu Y., and Huang C. Diallyl disulfide-induced G2/M arrest of human gastric cancer MGC803 cells involves activation of p38 MAP kinase pathways. World J Gastroenterol 10 (2004) 2731-2734
25. Rasola A., and Geuna M. A flow cytometry assay simultaneously detects independent apoptotic parameters. Cytometry 45 (2001) 151-157
26. Yoshida M., Kijima M., Akita M., and Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265 (1990) 17174-17179
27. Davie J.R., and Spencer V.A. Control of histone modifications. J Cell Biochem 75 (1999) 141-148
28. Riley D.J., Lee E., and Lee W.H. The retinoblastoma protein: more than a tumor suppressor. Annu Rev Cell Biol 10 (1994) 1-29
29. Tedesco D., Lukas J., and Reed S.I. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Genes Dev 16 (2002) 2946-2957
30. Russo G., Claudio P.P., Fu Y., Stiegler P., Yu Z., Macaluso M., et al. pRB 2/p130 target genes in non-small lung cancer cells identified by microarray analysis. Oncogene 22 (2003) 6959-6969
31. Baldi A., De Luca A., Claudio P.P., Baldi F., Giordano G.G., Tommasino M., et al. The Rb2/p130 gene product is a nuclear protein whose phosphorylation is cell cycle regulated. J Cell Biochem 59 (1995) 402-408
32. Paggi M.G., Baldi A., Bonetto F., and Giordano A. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 62 (1996) 418-430
33. King K.L., and Cidlowski J.A. Cell cycle regulation and apoptosis. Annu Rev Physiol 60 (1998) 601-617
34. Ren B., Cam H., Takahashi Y., Volkert T., Terragni J., Young R.A., et al. E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev 16 (2002) 245-256
35. Qian Y.W., Wang Y.C.J., Hollingsworth R.E., Jones D., Ling N., and Lee E. A retinoblastoma-binding protein related to a negative regulator of Ras in yeast. Nature 364 (1993) 648-652
36. Sarkaria J.N., Busby E.C., Tibbetts R.S., Roos P., Taya Y., Karnitz L.M., et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine 1. Cancer Res 59 (1999) 4375-4382
37. Owuor E.D., and Kong A.N. Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 64 (2002) 765-770
38. Li X., and Darzynkiewicz Z. The Schrodinger's cat quandary in cell biology: integration of live cell functional assays with measurements of fixed cells in analysis of apoptosis. Exp Cell Res 249 (1999) 404-412
39. Klampfer L., Cammenga J., Wisniewski H.G., and Nimer S.D. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 93 (1999) 2386
40. Ibrado A.M., Huang Y., Fang G., Liu L., and Bhalla K. Overexpression of Bcl-2 or Bcl-xL Inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56 (1996) 4743
41. Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., and Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48 (2001) 20-26
42. Kwon S.H., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277 (2002) 2073-2080
43. Lin R.J., Nagy L., Inoue S., Shao W., Miller Jr. W.H., and Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391 (1998) 811-814
44. Piekarz R.L., Robey R.W., Zhan Z., Kayastha G., Sayah A., Abdeldaim A.H., et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103 (2004) 4636-4643
45. Wu J.T., Archer S.Y., Hinnebusch B., Meng S., and Hodin R.A. Transient vs. prolonged histone hyperacetylation: effects on colon cancer cell growth, differentiation, and apoptosis. Am J Physiol Gastrointest Liver Physiol 280 (2001) 482-490
46. Hauser C., Schuettengruber B., Bartl S., Lagger G., and Seiser C. Activation of the mouse histone deacetylase 1 gene by cooperative histone phosphorylation and acetylation. Mol Cell Biol 22 (2002) 7820-7830
47. Kelly W.K., O'Connor O.A., and Marks P.A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11 (2002) 1695-1713
48. Sambucetti L.C., Fischer D.D., Zabludoff S., Kwon P.O., Chamberlin H., Trogani N., et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 274 (1999) 34940-34947
49. Sawa H., Murakami H., Kumagai M., Nakasato M., Yamauchi S., Matsuyama N., et al. Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol 107 (2004) 523-531
50. Vigushin D.M., and Coombes R.C. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13 (2002) 1-13